Literature Screening
Title, abstract, and full-text screening with blind dual review, conflict detection, and multi-reviewer collaboration.
Evidence synthesis platform
Multiple-reviewer screening, Cochrane-style meta-analysis, and PRISMA 2020 reporting in a single workflow - without moving data between tools.
No card required. Core workflow is free forever. Unlimited reviewers.

Teams
Blind review and arbitration
Statistics
IV, Mantel-Haenszel, and Peto pooling
PRISMA 2020
Flow diagrams from live screening counts
Real screens from a real review, in the order you’d actually use them.

Two reviewers work this same queue independently - EvidenceFlow flags where they disagree before anyone moves on.
Abstract viewer with AI relevance scores, include/exclude controls, conflict detection, and stage-by-stage progress.

Once extraction is done, EvidenceFlow pools your effect sizes and draws the forest plot from the same data - no copy-pasting into a separate stats tool.
Forest plots, funnel plots, PRISMA flow diagrams, and omics Manhattan plots - all generated from your extracted study data.

Your identification, screening, and inclusion counts feed this diagram directly - the numbers can't drift from what you actually screened.
A publication-ready PRISMA 2020 flow diagram, drawn live from your real identification, screening, and inclusion counts.
EvidenceFlow connects the entire evidence synthesis workflow in one place — from PICO to PRISMA, without hopping between tools.
Step 1 of 8
Define your research question and PICO framework. Every decision downstream - screening, extraction, synthesis - traces back to this starting point.
Research question
Do SGLT2 inhibitors reduce major adverse cardiovascular events versus usual care?
Reproducible workflow
Every decision is traceable.
Built for review teams
Blind dual review, not a solo inbox.
Portable results
Export CSV, JSON, and PDF anytime.
Blind dual review, automatic disagreement detection, and a full audit trail — every decision accountable, every reviewer’s progress visible.
Two reviewers screen independently. Neither sees the other’s include or exclude until you open arbitration.
Disagreements are flagged automatically. Unresolved records stay pending — they never silently count as included.
A third reviewer or the review manager records a final decision, with a rationale, on the conflicted study.
Every decision keeps who, when, and which stage. Progress is visible to the team without breaking blindness.
Integrates with the sources and standards you already use
From import to publication-ready output in one platform - no stitching tools together.
Title, abstract, and full-text screening with blind dual review, conflict detection, and multi-reviewer collaboration.
Pool effect sizes and quantify heterogeneity in minutes, using fixed and random effects models with publication-ready forest and funnel plots.
Synthesize evidence across populations and studies with GWAS variant aggregation, weighted gene-level RNA-seq summaries, and chromosome-level Manhattan plots.
Cut screening time by surfacing the most relevant studies first, with AI-powered relevance scoring against your research question.
Stay reporting-compliant with zero manual bookkeeping, using automated PRISMA flow diagrams that track counts at every stage.
Keep review teams in sync with role-based access, dual-reviewer screening, conflict detection, and a full audit trail.
Whether you’re running a single review or coordinating a department, EvidenceFlow fits the workflow.
Conduct PRISMA-compliant systematic reviews without switching between screening, extraction, and reporting tools.
Integrate GWAS, RNA-seq, and genomic datasets into your evidence synthesis alongside clinical literature.
Complete dissertations and evidence syntheses faster with AI-assisted screening and structured data extraction.
Run collaborative evidence reviews across departments with role-based access and a shared audit trail.
Methods are documented, analyses are reproducible, and your data stays portable - CSV, JSON, and PDF on every project.
All statistical methods are documented and auditable. Reproducible analyses with full parameter history.
Read the docsExport full data packages JSON, PDFs, and plots so every review step can be independently verified.
Methods guideYour data is never locked in. Every project exports as CSV, JSON, and PDF, ready for reuse elsewhere.
See export optionsImport from PubMed, RIS, and BibTeX, and generate PRISMA 2020-compliant flow diagrams out of the box.
PRISMA 2020 guideFree tools
Templates, calculators and guides you can use on their own, whether or not you use the platform.
FAQ
EvidenceFlow is an AI-assisted evidence synthesis platform for systematic reviews, meta-analysis, and omics research. It streamlines literature screening, structured data extraction, PRISMA 2020 reporting, and statistical analysis for researchers, clinicians, and bioinformaticians.
The core platform is free - literature import, manual screening, extraction, meta-analysis, and PRISMA reporting, with no subscription or seat limits. AI-assisted screening, extraction auto-fill, and manuscript drafting are a paid upgrade.
EvidenceFlow uses AI to prioritize studies based on your research question, PICO framework, and inclusion/exclusion criteria. Each study receives a suggested decision, confidence score, and explanation, while final screening decisions always remain under researcher control.
EvidenceFlow combines collaborative literature screening, PRISMA workflow management, statistical analysis, and AI-assisted evidence synthesis within a single platform, reducing the need to switch between multiple research tools.
Yes. EvidenceFlow automatically tracks study counts throughout the review process and generates PRISMA 2020-compliant flow diagrams that can be exported with your reports.
EvidenceFlow supports RIS, BibTeX, CSV, and direct PubMed search import, and you can upload full-text PDFs directly for full-text screening - making it easy to start new systematic review projects from existing reference libraries.
No. EvidenceFlow is proprietary hosted software. The source repository is not public, and the platform is not licensed for copying or redistribution except under a separate written agreement — see the Software License page. Third-party open-source libraries remain under their own licenses. The core platform is free to use; AI-assisted features are a paid upgrade. Project data stays portable through CSV, JSON, and PDF exports.
Yes. EvidenceFlow supports multi-reviewer projects with role-based access, dual-reviewer screening, conflict detection, and an audit trail of every decision.
EvidenceFlow's meta-analysis engine supports both fixed-effect and random-effects (DerSimonian–Laird) pooling, with heterogeneity statistics including Cochran's Q, I², and Tau², visualized as forest and funnel plots.
Yes. PRISMA 2020 flow diagrams are generated automatically from your screening decisions and can be exported as part of your PDF or Word report.
Yes. Export your review at any stage as PDF, Word, CSV, JSON, or PRISMA 2020 flow diagrams for sharing, publication, or further analysis.
Yes. Your projects remain private to your workspace unless you explicitly invite collaborators to join them.
EvidenceFlow is designed for researchers, clinicians, students, systematic review teams, and bioinformaticians conducting evidence synthesis across clinical and omics research.
Yes. EvidenceFlow includes workflows for aggregating GWAS variants, gene expression (RNA-seq) results, and other omics data alongside traditional systematic reviews.
Create a free account, import your references, and start screening with no configuration needed. AI-assisted screening, extraction, and manuscript drafting are available as a paid upgrade.